Dauren Adilbay1, Avery Yuan1, Paul B Romesser2,3, Richard J Wong1, Jatin P Shah1, Ashok R Shaha1, Michael R Tuttle4, Snehal Patel1, Nancy Y Lee2, Ian Ganly5. 1. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Medicine, Early Drug Development, Memorial Sloan Kettering Cancer Center, Early Drug Development, New York, NY, USA. 4. Department of Medicine, Endocrine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ganlyi@mskcc.org.
Abstract
BACKGROUND: The mainstay of treatment of well-differentiated thyroid cancer (WDTC) is surgery followed by adjuvant radioactive iodine therapy. Postoperative radiation therapy (PORT) is rarely used. OBJECTIVE: The aim of our study was to report our experience of patients with WDTC who were selected to receive PORT. MATERIALS AND METHODS: After Institutional Review Board approval, patients who received PORT were identified from a departmental database of 6259 patients with WDTC treated with primary surgery from 1986 to 2015. We carried out propensity matching to compare outcomes with a cohort of patients who did not receive PORT. The main outcome of interest was central neck recurrence-free probability (CNRFP), while secondary outcomes were lateral neck recurrence-free probability (LNRFP), disease-specific survival (DSS), and overall survival (OS). RESULTS: From 6259 patients, 32 (0.5%) patients with a median age of 65.2 years received PORT. Tall-cell variant papillary thyroid carcinoma was the most common pathology (45%). Patients who received PORT had no difference in CNRFP compared with patients treated without PORT (10-year CNRFP 88% vs. 73%; p = 0.18). Furthermore, patients who received PORT had superior LNRFP (10-year LNRFP 100% vs. 62%; p = 0.001) compared with the no-PORT cohort. Despite this, patients who received PORT had similar DSS (71% PORT vs. 75% no-PORT) and OS (65% PORT vs. 58% no-PORT group) as the no-PORT cohort. CONCLUSIONS: Our data show that select patients who received PORT had improved locoregional recurrence-free probability; however, this did not translate into improved DSS and OS. At our institution, we recommend the use of PORT only in highly selected patients with locally advanced primary tumors who are deemed to have a high risk of central neck recurrence for which salvage surgery would result in unacceptable risk to the airway.
BACKGROUND: The mainstay of treatment of well-differentiated thyroid cancer (WDTC) is surgery followed by adjuvant radioactive iodine therapy. Postoperative radiation therapy (PORT) is rarely used. OBJECTIVE: The aim of our study was to report our experience of patients with WDTC who were selected to receive PORT. MATERIALS AND METHODS: After Institutional Review Board approval, patients who received PORT were identified from a departmental database of 6259 patients with WDTC treated with primary surgery from 1986 to 2015. We carried out propensity matching to compare outcomes with a cohort of patients who did not receive PORT. The main outcome of interest was central neck recurrence-free probability (CNRFP), while secondary outcomes were lateral neck recurrence-free probability (LNRFP), disease-specific survival (DSS), and overall survival (OS). RESULTS: From 6259 patients, 32 (0.5%) patients with a median age of 65.2 years received PORT. Tall-cell variant papillary thyroid carcinoma was the most common pathology (45%). Patients who received PORT had no difference in CNRFP compared with patients treated without PORT (10-year CNRFP 88% vs. 73%; p = 0.18). Furthermore, patients who received PORT had superior LNRFP (10-year LNRFP 100% vs. 62%; p = 0.001) compared with the no-PORT cohort. Despite this, patients who received PORT had similar DSS (71% PORT vs. 75% no-PORT) and OS (65% PORT vs. 58% no-PORT group) as the no-PORT cohort. CONCLUSIONS: Our data show that select patients who received PORT had improved locoregional recurrence-free probability; however, this did not translate into improved DSS and OS. At our institution, we recommend the use of PORT only in highly selected patients with locally advanced primary tumors who are deemed to have a high risk of central neck recurrence for which salvage surgery would result in unacceptable risk to the airway.
Authors: Benjamin D Rosenbluth; Victoria Serrano; Laura Happersett; Ashok R Shaha; R Michael Tuttle; Ashwatha Narayana; Suzanne L Wolden; Kenneth E Rosenzweig; Lanceford M Chong; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-12 Impact factor: 7.038
Authors: Ana P Kiess; Nishant Agrawal; James D Brierley; Umamaheswar Duvvuri; Robert L Ferris; Eric Genden; Richard J Wong; R Michael Tuttle; Nancy Y Lee; Gregory W Randolph Journal: Head Neck Date: 2015-12-30 Impact factor: 3.147
Authors: Victoria Harries; Laura Y Wang; Marlena McGill; Bin Xu; R Michael Tuttle; Richard J Wong; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Snehal G Patel; Ian Ganly Journal: Surgery Date: 2019-09-09 Impact factor: 3.982
Authors: Erik K Alexander; Elizabeth N Pearce; Gregory A Brent; Rosalind S Brown; Herbert Chen; Chrysoula Dosiou; William A Grobman; Peter Laurberg; John H Lazarus; Susan J Mandel; Robin P Peeters; Scott Sullivan Journal: Thyroid Date: 2017-03 Impact factor: 6.568
Authors: Paul B Romesser; Eric J Sherman; Ashok R Shaha; Ming Lian; Richard J Wong; Mona Sabra; Shyam S Rao; James A Fagin; R Michael Tuttle; Nancy Y Lee Journal: J Surg Oncol Date: 2014-06-24 Impact factor: 3.454
Authors: Laith Samhouri; Jan Kriz; Khaled Elsayad; Mohammed Channaoui; Andreas Pascher; Burkhard Riemann; Rainer Wiewrodt; Uwe Haverkamp; Sergiu Scobioala; Hans Theodor Eich Journal: Anticancer Res Date: 2020-06 Impact factor: 2.480
Authors: Thomas H Beckham; Paul B Romesser; Andries H Groen; Christopher Sabol; Ashok R Shaha; Mona Sabra; Thomas Brinkman; Daniel Spielsinger; Sean McBride; C Jillian Tsai; Nadeem Riaz; R Michael Tuttle; James A Fagin; Eric J Sherman; Richard J Wong; Nancy Y Lee Journal: Thyroid Date: 2018-09 Impact factor: 6.568